Which medications in the drug class Anti-Nectin-4 Monoclonal Antibodies are used in the treatment of Bladder Cancer?

Updated: Feb 23, 2021
  • Author: Kara N Babaian, MD, FACS; Chief Editor: Bradley Fields Schwartz, DO, FACS  more...
  • Print

Anti-Nectin-4 Monoclonal Antibodies

Nectin-4 is a cell adhesion molecule that is expressed on many solid tumors.

Enfortumab vedotin (Padcev, enfortumab vedotin-ejfv)

Enfortumab vedotin is an antibody-drug conjugate (ADC) composed of an anti-nectin-4 monoclonal antibody attached to the cell-killing agent, monomethylauristatin E (MMAE). Once the antibody attaches to nectin-4 that is expressed on the tumor, the complex is internalized in the lysosome, which releases MMAE. Enfortumab vedotin is indicated for locally advanced or metastatic urothelial cancer in patients who have received a PD-1/L1 inhibitor and platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced, or metastatic setting.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!